207 related articles for article (PubMed ID: 35958614)
1. An immune-related gene prognostic risk index for pancreatic adenocarcinoma.
Su Y; Qi R; Li L; Wang X; Li S; Zhao X; Hou R; Ma W; Liu D; Zheng J; Shi M
Front Immunol; 2022; 13():945878. PubMed ID: 35958614
[TBL] [Abstract][Full Text] [Related]
2. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
Tian C; Li X; Ge C
Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
[TBL] [Abstract][Full Text] [Related]
3. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
4. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
6. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
7. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
8. Development of an autophagy-related signature in pancreatic adenocarcinoma.
Yue P; Zhu C; Gao Y; Li Y; Wang Q; Zhang K; Gao S; Shi Y; Wu Y; Wang B; Xie J; Meng X
Biomed Pharmacother; 2020 Jun; 126():110080. PubMed ID: 32203889
[TBL] [Abstract][Full Text] [Related]
9. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
10. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
Chen Y; Li ZY; Zhou GQ; Sun Y
Clin Cancer Res; 2021 Jan; 27(1):330-341. PubMed ID: 33097495
[TBL] [Abstract][Full Text] [Related]
11. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma.
Liu Q; Li R; Wu H; Liang Z
BMC Cancer; 2023 Mar; 23(1):226. PubMed ID: 36894917
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
13. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
15. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
[TBL] [Abstract][Full Text] [Related]
16. Gene coexpression network approach to develop an immune prognostic model for pancreatic adenocarcinoma.
Gu X; Zhang Q; Wu X; Fan Y; Qian J
World J Surg Oncol; 2021 Apr; 19(1):112. PubMed ID: 33845841
[TBL] [Abstract][Full Text] [Related]
17.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
19. Weighted Gene Co-Expression Network Analysis Reveals Six Hub Genes Involved in and Tight Junction Function in Pancreatic Adenocarcinoma and their Potential Use in Prognosis.
Xia WX; Zhang LH; Liu YW
Genet Test Mol Biomarkers; 2019 Dec; 23(12):829-836. PubMed ID: 31821092
[No Abstract] [Full Text] [Related]
20. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
Li A; Hou S; Chen J; Jiang Y
Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
